摘要
自发性细菌性腹膜炎(SBP)是肝硬化患者常见的并发症,也是肝硬化患者进展至急性失代偿期的重要诱因,是临床治疗的重点和难点。SBP致病菌随时间变化、地域差异而不同,经证实革兰阳性菌及多耐药菌的检出率逐年增加,因此基于既往指南的抗菌药物治疗方案是否仍然适用有待进一步探讨。本文重点介绍不同研究人群、不同地域、不同时间、不同感染方式下肝硬化合并SBP的致病菌特征,并针对SBP致病菌的变化,归纳经验性抗菌治疗方案,以期为临床治疗提供理论依据。
Spontaneous bacterial peritonitis(SBP)is a common complication in patients with liver cirrhosis,and it is also an important inducement for patients with liver cirrhosis to develop into an acute decompensated stage,and thereby has become the concern and difficulties of clinical treatment.SBP pathogenic bacteria varies with time and region,and the confirmed detection rate of Gram-positive bacteria and multidrug-resistant bacteria has been increasing year by year.Therefore,whether the antimicrobial treatment plan based on the previous guidelines is still applicable remains to be further explored.This paper focuses on introducing the pathogenic bacteria characteristics for cirrhosis combined with SBP in different study populations,different regions,different time,and different infection modes,and further summarizes empirical antimicrobial treatment plan according to the changes of SBP pathogenic bacteria,in order to provide theoretical basis for clinical treatment.
作者
李苏萌
刘京
郑昕
Li Sumeng;Liu Jing;Zheng Xin(Department of Infectious Diseases,Institute of Infection and Immunology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China)
出处
《中华肝脏病杂志》
CSCD
北大核心
2021年第7期716-720,共5页
Chinese Journal of Hepatology
关键词
肝硬化
自发性细菌性腹膜炎
耐药菌
抗菌治疗
Liver cirrhosis
Spontaneous bacterial peritonitis
Multidrug-resistant bacteria
Antimicrobial strategies
